Immunis is a biotechnology company developing IMM01-STEM, a biologic therapy that utilizes natural human immune modulators to enhance muscle regeneration and metabolism. The company is conducting a Phase 1/2a clinical trial to evaluate the therapy's effectiveness in treating age-related muscle atrophy.
Funding
$37M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Age-related muscle atrophy leads to decreased mobility, increased risk of falls, and reduced overall quality of life for the elderly. Current treatments offer limited efficacy and often come with significant side effects, leaving a gap in effective therapeutic options.
Solution
Immunis is developing IMM01-STEM, a biologic therapy composed of natural human immune modulators, to enhance muscle regeneration and metabolism. This investigational therapy utilizes cell culture techniques to deliver a product containing all-natural, all-human immune modulators in their natural relative concentrations. Preclinical data suggests that IMM01-STEM promotes muscle regeneration and improves metabolic function. The company is currently evaluating the effects of IMM01-STEM in a Phase 1/2a clinical trial for age-related muscle atrophy.
Target Audience
The primary target audience includes elderly individuals experiencing age-related muscle atrophy and the healthcare providers who treat them.
Features
- Multi-active biologic therapy composed of natural human immune modulators
- Utilizes cell culture techniques to preserve natural concentrations of immune modulators
- Designed to enhance muscle regeneration and improve metabolic function
- Currently in Phase 1/2a clinical trials for age-related muscle atrophy